Regeneron Pharmaceuticals News and Activities
Presence
Regeneron Pharmaceuticals develops and sells medicines for serious diseases. Its products include prescription biologic therapies and research services for patients, healthcare providers, and research partners.
Regeneron Pharmaceuticals products and services overview:
- Biologic medicines
- Eye disease treatments
- Cancer treatments
- Inflammation treatments
- Rare disease therapies
- Drug discovery services
Revenue: ~$14 billion
Employees: 15,000
Headquarters: Tarrytown, United States (USA)
Regeneron Pharmaceuticals is one of the...
- Forbes Global 2000 (#431);
- Fortune 500 (#311);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Regeneron Pharmaceuticals is a company listed under the stock ticker REGN (US).
They are in:
- Pharmaceuticals50%
- Biotechnology50%
Acquisition, funding and merger involving Regeneron Pharmaceuticals.
- Regeneron Pharmaceuticals has announced the acquisition of 23andMe (posted on May 20 2025).
Executives
View the org chart displaying its 95 main executives
Most searched biographies at Regeneron Pharmaceuticals
- Leonard Schleifer, President, Chief Executive Officer, Director
- Bonnie Bassler, Chairman of the Board
- Joseph Goldstein, Director
Popular executive movements at Regeneron Pharmaceuticals
- Benjamin Yocum, Senior Vice President, Manufacturing Operations, has left the company (posted on March 30 2026).
- Jack Quinn, Head, State Government Relations, has left the company (posted on March 30 2026).
- Meredith Marlin, who was Vice President, Head of Total Rewards, is promoted to Senior Vice President, Total Rewards (posted on January 12 2026).
Click here to view some more movements at Regeneron Pharmaceuticals
Create your alert
to follow the executive moves at Regeneron Pharmaceuticals.
Pharmaceuticals
Regeneron Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Regeneron Pharmaceuticals
- CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis | Regeneron Pharmaceuticals Inc.
- https://newsroom.regeneron.com/node/24391/pdf
- https://newsroom.regeneron.com/node/24386/pdf
- Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus) | Regeneron Pharmaceuticals Inc.
- Dupixent® (dupilumab) Significantly Reduced Severe Asthma Attacks in Children and is the Only Biologic to Demonstrate Improvement in Children's Lung Function in a Randomized Phase 3 Trial | Regeneron Pharmaceuticals Inc.
- Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020 | Regeneron Pharmaceuticals Inc.
- Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients | Regeneron Pharmaceuticals Inc.
- Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50% | Regeneron Pharmaceuticals Inc.
- Press Releases | Regeneron Pharmaceuticals Inc.
- Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO | Regeneron Pharmaceuticals Inc.
- View more press releases Close
Social media about Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Regeneron Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
